Eli Lilly Valuation
| LLY Stock | USD 1,010 13.70 1.34% |
At this time, the firm appears to be fairly valued. Eli Lilly shows a prevailing Real Value of $974.08 per share. The current price of the firm is $1009.52. Our model computes the value of Eli Lilly from reviewing the firm fundamentals such as Current Valuation of 1 T, shares outstanding of 943.36 M, and Profit Margin of 0.32 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eli Lilly's valuation include:
Price Book 36.3769 | Enterprise Value | Enterprise Value Ebitda 31.5684 | Price Sales 14.6111 | Forward PE 27.1739 |
Fairly Valued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1009.52 | Real 974.08 | Target 1211.21 | Hype 1009.42 | Naive 1005.07 |
The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eli Lilly's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eli Lilly's intrinsic value based on its ongoing forecasts of Eli Lilly's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eli Lilly's closest peers.
Eli Lilly Cash |
|
Eli Revenue by Product
Eli Lilly Total Value Analysis
Eli Lilly and is now expected to have company total value of 1 T with market capitalization of 952.34 B, debt of 42.5 B, and cash on hands of 7.27 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Eli Lilly fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1 T | 952.34 B | 42.5 B | 7.27 B |
Eli Lilly Investor Information
About 85.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.9. Eli Lilly recorded earning per share (EPS) of 22.92. The entity last dividend was issued on the 13th of February 2026. The firm had 2:1 split on the 16th of October 1997. Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.48 | 0.4556 |
|
| |||||
| Total Cash From Operating Activities | 17.7 B | 16.8 B |
|
| |||||
| Operating Income | 31.2 B | 29.7 B |
|
|
Eli Lilly Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eli Lilly has an asset utilization ratio of 57.95 percent. This suggests that the Company is making $0.58 for each dollar of assets. An increasing asset utilization means that Eli Lilly and is more efficient with each dollar of assets it utilizes for everyday operations.Eli Lilly Profitability Analysis
Based on the key profitability measurements obtained from Eli Lilly's financial statements, Eli Lilly's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Eli Lilly's ability to earn profits and add value for shareholders.Net Income | First Reported 1985-09-30 | Previous Quarter 5.6 B | Current Value 6.6 B | Quarterly Volatility 1.1 B |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.8379 |
|
| |||||
| Operating Profit Margin | 0.48 | 0.4556 |
|
| |||||
| Pretax Profit Margin | 0.26 | 0.3948 |
|
|
For Eli Lilly profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eli Lilly to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eli Lilly utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eli Lilly's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eli Lilly over time as well as its relative position and ranking within its peers.
Eli Lilly Earnings per Share Projection vs Actual
The next projected EPS of Eli Lilly is estimated to be 7.2204 with future projections ranging from a low of 3.63 to a high of 8.1638. Eli Lilly's most recent 12-month trailing earnings per share (EPS TTM) is at 22.92. Please be aware that the consensus of earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.Eli Lilly Earnings Estimation Breakdown
The calculation of Eli Lilly's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eli Lilly is estimated to be 7.2204 with the future projection ranging from a low of 3.63 to a high of 8.1638. Please be aware that this consensus of annual earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
3.63 Lowest | Expected EPS | 8.16 Highest |
Eli Lilly Earnings Projection Consensus
Suppose the current estimates of Eli Lilly's value are higher than the current market price of the Eli Lilly stock. In this case, investors may conclude that Eli Lilly is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eli Lilly's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 29 | 84.93% | 7.54 | 7.2204 | 22.92 |
Eli Lilly Ownership Allocation
Eli Lilly holds a total of 943.36 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Please note that on February 3, 2026, Representative David Taylor of US Congress acquired under $15k worth of Eli Lilly's common stock.Eli Lilly Profitability Analysis
The company reported the last year's revenue of 65.18 B. Total Income to common stockholders was 20.64 B with profit before taxes, overhead, and interest of 54.13 B.Eli Lilly Past Distributions to stockholders
About Eli Lilly Valuation
Our relative valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 54.6 B | 57.3 B | |
| Pretax Profit Margin | 0.39 | 0.26 | |
| Operating Profit Margin | 0.46 | 0.48 | |
| Net Profit Margin | 0.32 | 0.33 | |
| Gross Profit Margin | 0.84 | 0.62 |
Eli Lilly Quarterly Retained Earnings |
|
A single share of Eli Lilly represents a small ownership stake in the entity. As a stockholder of Eli, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Eli Lilly Dividends Analysis For Valuation
Dividend Paid And Capex Coverage Ratio is likely to rise to 1.49 in 2026, despite the fact that Dividends Paid is likely to grow to (5.1 B). . At this time, Eli Lilly's Retained Earnings are fairly stable compared to the past year. Price Earnings Ratio is likely to rise to 49.10 in 2026, whereas Retained Earnings Total Equity is likely to drop slightly above 10.8 B in 2026.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -5.4 B | -5.1 B | |
| Dividend Yield | 0.01 | 0.01 | |
| Dividend Payout Ratio | 0.26 | 0.20 | |
| Dividend Paid And Capex Coverage Ratio | 1.27 | 1.49 |
There are various types of dividends Eli Lilly can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Eli shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Eli Lilly and directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Eli pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Eli Lilly by the value of the dividends paid out.
Eli Lilly Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 898 M | |
| Quarterly Earnings Growth Y O Y | 0.514 | |
| Forward Price Earnings | 27.1739 |
Eli Lilly Current Valuation Indicators
Valuation refers to the process of determining the present value of Eli Lilly and and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Eli we look at many different elements of the entity such as Eli's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Eli Lilly, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Eli Lilly's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Eli Lilly's worth.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.